Inflectra Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to high cost of originator tnf inhibitors, regulatory biosimilar approvals, growing autoimmune disease burden, hospital formulary adoption, payer cost containment strategies.

The growth in the forecast period can be attributed to biosimilar friendly regulations, expanding patient access to biologics, growth in inflammatory diseases, competitive pricing pressure, increasing physician familiarity. Major trends in the forecast period include rising adoption of biosimilars, cost driven switching from originator biologics, expansion of autoimmune disease treatment, physician confidence in biosimilar safety, hospital led biosimilar procurement.

The rising prevalence of autoimmune diseases is expected to drive the growth of the inflectra market in the coming years. Autoimmune diseases occur when the immune system mistakenly attacks healthy cells, causing inflammation and damage to various tissues and organs. The increasing prevalence of these diseases is attributed to factors such as dietary changes, exposure to pollutants, lifestyle behaviors, and climate change. This surge in autoimmune conditions impacts the inflectra market by creating a higher demand for effective treatment options, as more patients seek therapies like Inflectra to manage conditions such as rheumatoid arthritis and Crohn's disease. Inflectra works by inhibiting tumor necrosis factor-alpha (TNF-α), a key pro-inflammatory protein, to reduce inflammation. For example, in September 2023, the IBD Clinical and Research Centre, a Canada-based organization dedicated to improving the lives of patients with Crohn's disease and ulcerative colitis, reported that over 320,000 Canadians were living with inflammatory bowel disease (IBD) in 2023, with a prevalence rate of 825 per 100,000. The prevalence is expected to rise by 2.44% annually, with projections indicating that 1.1% of Canada's population, or 470,000 people, will have IBD by 2035. As a result, the increasing prevalence of autoimmune diseases is driving the growth of the inflectra market.

The growing number of clinical trials is expected to further drive the growth of the inflectra market. Clinical trials are research studies involving human participants to assess the effects of new medical treatments, including drugs, devices, and behavioral interventions, on health outcomes. They are crucial for determining the safety and effectiveness of these treatments before they can be widely used. The rise in clinical trials is attributed to the increasing demand for innovative therapies, advancements in medical research, the need for diverse participant representation, and the urgency to address unmet medical needs. This surge in clinical trials benefits the inflectra market by generating robust data on its safety and efficacy, enhancing its market positioning, and boosting demand as a treatment option for autoimmune diseases. For example, in April 2025, according to the National Library of Medicine, a U.S.-based government agency, ClinicalTrials.gov listed 404,637 interventional clinical trials by March 2025, with 27,751 new trials launched in 2023. Therefore, the growing number of clinical trials is a key driver for the growth of the inflectra market.

A key trend in the inflectra market is the focus on developing innovative products, such as subcutaneous infliximab biosimilars, to offer a more convenient and effective maintenance treatment option for patients with inflammatory bowel disease. The subcutaneous infliximab biosimilar is an injectable form of infliximab that simplifies the administration method for treating autoimmune diseases. For example, in October 2023, Celltrion USA, a U.S.-based subsidiary of Celltrion, a biopharmaceutical company, announced the FDA approval of ZYMFENTRA (infliximab-dyyb), the first and only subcutaneous formulation of infliximab for the maintenance treatment of moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC) in adults. This novel subcutaneous formulation ensures stable elevated serum infliximab levels, providing a more convenient and flexible option for patients and healthcare providers. The approval is important as it alleviates the daily burden of managing inflammatory bowel disease and enhances patient control over their treatment plans.

Major companies operating in the inflectra market are Celltrion Inc.

Europe was the largest region in the inflectra market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflectra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the inflectra market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the inflectra market by increasing costs for monoclonal antibody production materials and cross border biologics distribution. Hospital and specialty clinic segments in europe and north america are most affected due to biologic import dependence. These tariffs can influence pricing competitiveness against originator drugs. However, tariffs are supporting regional biosimilar manufacturing and strengthening localized biologics supply chains.

The inflectra market research report is one of a series of new reports that provides inflectra market statistics, including inflectra industry global market size, regional shares, competitors with a inflectra market share, detailed inflectra market segments, market trends and opportunities, and any further data you may need to thrive in the inflectra industry. This inflectra market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Inflectra, also known by its generic name infliximab-dyyb, is a biosimilar to Remicade (infliximab) and is classified as a tumor necrosis factor (TNF) inhibitor. It is primarily used to treat a range of autoimmune conditions, such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. This monoclonal antibody specifically targets and inhibits TNF-alpha, a key pro-inflammatory protein that plays a significant role in immune responses.

The primary patient demographics for Inflectra include both pediatric and adult patients. Pediatric patients, who are children and adolescents under the age of 18, may suffer from autoimmune diseases like Crohn's disease or ulcerative colitis. The drug is applied in the treatment of conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and other related autoimmune disorders. The distribution of Inflectra occurs through several channels, including hospitals, specialty clinics, online pharmacies, and retail pharmacies.

The inflectra market consists of sales of lyophilized powder and intravenous infusion. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.